ArticleMikrochimica acta2026
An autosampling microfluidic chip enables FEN1-aided recombinase polymerase amplification to rapidly detect multiple urinary tract infection pathogens on-site.
Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Urinary tract infections (UTIs) require rapid pathogen identification at the point of care (POCT) to enable timely therapy and reduce empirical antibiotic use. Here, we report an autosampling microfluidic platform that integrates a vacuum-driven PDMS chip with FEN1-aided recombinase polymerase amplification (FARPA), a syringe-filter enrichment module, and a rapid lysis protocol (1-min ultrasonication followed by 2-min thermal lysis at 98˚Ϲ). The round chip partitions each sample into five reaction chambers with preloaded primers/probes, enabling parallel detection of five common UTI pathogens (Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, Enterococcus faecium, and Enterococcus faecalis) across five samples in a single run. Using DNA templates, the chip assay detects down to 5 copies per reaction. With syringe-filter enrichment and rapid lysis, the system achieves the sample-level limit of detection of 10^2 CFU/mL (in urine matrix) and completes the sample-to-answer workflow within 55 min using a battery-powered handheld fluorescence reader. In a clinical study of 299 specimens (urine, ascitic fluid, pleural effusion, abdominal drainage, and bladder-puncture urine), the chip-FARPA results showed 91.1% sensitivity (72/79 culture-positive detected) and 100% specificity versus bacterial culture, supporting a portable and low-cost POCT solution for on-site UTI pathogen screening.>
Indexed as
Identifiers
41945152What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.